Elsewhere online
May 11, 2015

Drugmaker Puts $20 Million Into AIDS Cure Partnership with UNC

Pharmaceutical giant GlaxoSmithKline and the University of North Carolina are teaming up to establish a research institute and a company that will seek a cure for HIV/AIDS, The New York Times reports. The British drugmaker will provide $20 million over five years to finance the research center at the school's flagship Chapel Hill campus, advancing a trend of drug firms working directly with university scientists to tackle specific diseases.

The new company, Qura Therapeutics, will be jointly owned by GlaxoSmithKline and the university and will have the rights to take any new discoveries to market. The work in North Carolina will focus on developing therapies to alert a patient's body to the presence of HIV in cells where the virus hides in a dormant state, and direct the immune system to destroy the infected cells, an approach known as shock and kill.